From June 24th to 26th, 2025, the 23rd CPHI China was grandly held in Shanghai. As a landmark exhibition for China's pharmaceutical industry to go global, CPHI China not only brings together the pioneering forces of the global pharmaceutical industry but also builds a platform for deep connection between the international market and high-quality resources.。
Mr. Zhang Qiang, Chairman of Sichuan Xieli Pharmaceutical Co., Ltd., personally led a professional team of more than 20 people from core departments such as the Domestic Sales, International Trading, R&D,BD and Quality departments to participate in the exhibition, fully demonstrating the company's high attention to this industry event.
In this exhibition, Sichuan Xieli Pharmaceutical Co., Ltd. took "professionalization, internationalization, and branding" as its core strategy, comprehensively showcasing the company's core advantages in API R&D, lean production, and full-process quality management. It also deeply promoted customer relationship management and market expansion through multi-level and multi-dimensional business negotiations and technical exchanges.
During the three-day exhibition, Xieli team made precise efforts in deepening existing cooperation, expanding incremental markets, and tapping into innovative momentum.
1. Deepening existing cooperation: Relying on the exhibition platform, the company had in-depth dialogues with long-term partners, conducted in-depth discussions on issues such as product quality optimization, supply chain collaboration upgrading, and joint R&D innovation, further consolidating the cooperation foundation and improving the cooperation level
2. Expanding incremental markets: For potential customer groups, our professional team comprehensively demonstrated the company's technical strength and service capabilities in the API field through systematic product explanations, technical Q&A, and case sharing, successfully attracting the attention of many new industry partners and laying a solid foundation for subsequent business expansion.
3. Tapping into innovative momentum: Actively seizing the industry exchange opportunities brought by the exhibition, the company had extensive contacts with upstream and downstream enterprises and scientific research institutions, deeply explored new business opportunities such as technical cooperation and market development, and injected new momentum into the sustainable innovative development of Xieli Pharma.
In fact, deepening the CPHI series of exhibitions has long been the "globalization code" of Xieli Pharma. In the past exhibition history, the company's core products, with specialized technology and processes, have attracted customers from dozens of countries and regions such as Russia, Japan, and Egypt to negotiate cooperation, effectively enhancing the company's brand awareness in the international market. The company's products in the field of plant extraction and natural active ingredients, through continuous technical investment and strict quality control, have entered multiple markets in Europe, the Americas, Southeast Asia, and the Middle East, continuously exploring the application potential of products in the global market.
Today, industry exhibitions have become a key hub for connecting market supply and demand, promoting technological innovation, and leading industrial trends. Sichuan Xieli Pharmaceutical Co., Ltd. will base itself on the industry height, build a systematic exhibition strategy, deeply participate in more than ten top domestic and foreign pharmaceutical exhibitions every year, and continue to deepen its industry influence. In the future, the company will continue to optimize the exhibition strategic layout, keep up with industry trends, strengthen technological innovation and quality management, and join hands with global partners in a more open attitude to contribute "Xieli Power" to the high-quality development of the pharmaceutical industry.
Declaration: The products involved in this article are all pharmaceutical raw materials, intermediates, or plant extracts, strictly used for industrial purposes and drug production, and are not terminal drugs directly facing consumers. The promotional content strictly complies with the requirements of the Advertising Law and relevant laws and regulations.
